Charles River Laboratories Profit Margin 2006-2018 | CRL

Current and historical gross margin, operating margin and net profit margin for Charles River Laboratories (CRL) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Charles River Laboratories net profit margin as of September 30, 2018 is 6.39%.
Charles River Laboratories Annual Profit Margins
Charles River Laboratories Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical Services $6.152B $1.858B
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $55.794B 11.53
ICON (ICLR) Ireland $7.366B 23.09
PRA Health Sciences (PRAH) United States $6.726B 27.46
Premier (PINC) United States $5.263B 17.86
INC Research Holdings (SYNH) United States $4.636B 18.71
HealthEquity (HQY) United States $4.100B 80.15
Teladoc (TDOC) United States $3.677B 0.00
NovoCure (NVCR) Jersey $3.283B 0.00
AMN Healthcare Services Inc (AMN) United States $2.750B 18.87
BioTelemetry (BEAT) United States $2.205B 38.95
Medpace Holdings (MEDP) United States $1.982B 24.52
IKang Healthcare (KANG) China $1.272B 63.17
Intrexon (XON) United States $1.186B 0.00
Healthways (TVTY) United States $1.115B 13.72
CareDx (CDNA) United States $1.086B 0.00
Natera (NTRA) United States $1.020B 0.00
China Cord Blood (CO) China $0.733B 20.10
Surgery Partners (SGRY) United States $0.649B 0.00
Apollo Medical Holdings (AMEH) United States $0.619B 0.00
Establishment Labs Holdings (ESTA) $0.482B 0.00
Civitas Solutions (CIVI) United States $0.457B 8.30
OncoCyte (OCX) United States $0.058B 0.00
Interpace Diagnostics (IDXG) United States $0.029B 0.00
Cancer Genetics (CGIX) United States $0.010B 0.00
OpGen (OPGN) United States $0.008B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.002B 0.00